EP0815211A1 - Neue, definierte enzymmischungen zur zellgewinnung und für die wundbehandlung - Google Patents

Neue, definierte enzymmischungen zur zellgewinnung und für die wundbehandlung

Info

Publication number
EP0815211A1
EP0815211A1 EP96907436A EP96907436A EP0815211A1 EP 0815211 A1 EP0815211 A1 EP 0815211A1 EP 96907436 A EP96907436 A EP 96907436A EP 96907436 A EP96907436 A EP 96907436A EP 0815211 A1 EP0815211 A1 EP 0815211A1
Authority
EP
European Patent Office
Prior art keywords
collagenase
cells
gly
pro
enzymes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96907436A
Other languages
German (de)
English (en)
French (fr)
Inventor
Claus Otto Markert
Hans Thom
Jürgen Weymann
Wolfgang Zahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19532906A external-priority patent/DE19532906A1/de
Application filed by Knoll GmbH filed Critical Knoll GmbH
Publication of EP0815211A1 publication Critical patent/EP0815211A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6448—Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to the use of defined mixtures of purified enzymes from Clostridium histolyticum for the reproducible, standardized extraction of cells or tissue fragments from human or animal tissue and the use of these purified enzymes for wound treatment.
  • the normally used and recommended collagenase-containing preparations (2) are obtained from culture filtrates of the bacterial strain Clostridium histolyticum and, in addition to various collagenases and proteases (3a), (3b), also contain cleavage products of these enzymes formed by proteolysis, as well as others, some of which are harmful acting and unknown components.
  • Collagenase fraction and purified trypsin from bovine pancreas isolated.
  • the collagenase fraction used was enriched However, 2 was not defined in terms of its content of various enzymes and also contained, for example, small amounts of clostripain.
  • the success of the isolation was not significantly different from that which was obtained when using undefined compositions containing collagenase. Satisfactory tissue disintegration could not be achieved with individual components of the mixture.
  • trypsin for cell isolation is not without problems, since this proteolytic enzyme attacks membrane proteins. For example, insulin binding to liver membranes and adipocytes is negatively influenced (5).
  • Hefley (6), (7) used mixtures of purified collagenase fractions to isolate bone cells from the skull cap of mice (6). Earlier (7) the author described that a mixture of a purified collagenase fraction can be used together with a neutral protease to successfully isolate these cells. In both studies, however, eluates from column fractionations were used, whose content of various collagenases, which differ in their substrate specificity, and of other components was not known.
  • the invention relates to the individual enzymes collagenase HP, collagenase AZ and elastase, in high purity and mixtures thereof.
  • Collagenase HP has a specific activity of at least 20 U / mg, preferably at least 50 U / mg in the Grclumann and Nordwig (11) test with the synthetic hexapeptide Z-Gly-Pro-Gly-Gly-Pro-Ala as substrate. For pharmaceutical purposes, it preferably has a specific activity of 100 U / mg or more.
  • Collagenase AZ has a specific activity of at least 10 U / mg, preferably at least 30 U / mg in the test according to Mandl et al. (12) using azocoll as substrate. For phar a- for therapeutic purposes, it preferably has a specific activity of 50 U / mg or more.
  • Elastase has a specific activity of at least 2 U / mg, preferably at least 5 U / mg in the test with elastin from the neck band of the cattle as a substrate. For pharmaceutical purposes, it preferably has a specific activity of 12 U / mg or more.
  • the invention further relates to the use of a mixture of collagenase HP and elastase, optionally with the addition of collagenase AZ and / or clostripain, for the isolation of cells or tissue fragments from human or animal tissue.
  • the invention further relates to the direct or indirect use of these enzymes, alone or as a component of mixtures, for medical applications, e.g. in wound treatment.
  • the mixtures can, for example, be packaged in vials in lyophilized form in such a way that they are sufficient for disintegration from an individual rat liver (approx. 9-11 g wet weight of the organ).
  • Suitable mixtures are those which consist of at least two of the purified enzymes collagenase HP (50-300 U; preferably 70-170 U) and elastase (5-70 U, preferably 10-25 U) and optionally an addition of collagenase AZ (1-20, preferably 2-8 U) and / or clostripain (10-280 U, preferably 20-50 U) contain.
  • the numbers given indicate the amounts in one unit of the mixture - for example in a vial - available.
  • the purity criterion for the enzymes used is their respective specific activity and their uniformity detection in the electrophoretic methods commonly used for this purpose (SDS gel electrophoresis, isoelectric focusing and electrophoresis on agarose gel).
  • the specific activity of the purified enzymes is up to 100 times higher than that of the starting material.
  • a major advantage is that a time-consuming and costly inspection of batches is no longer necessary, since the production of purified enzymes is based on known properties. This eliminates the workload that is necessary for the functional characterization of the cells, or at least it is reduced. For these reasons, the number of animal experiments can be reduced in many areas.
  • tissue fragments and / or cells are suitable for the use of the mixtures of purified enzymes according to the invention:
  • the biliary tract the blood system, glands, the vascular system, the brain, the skin, the heart, the intes inu, Langerhans' islets, the liver, the lungs, the stomach, the spleen, muscles, the Umbilical cord, nerves, the kidney, the pancreas, the spinal cord, the thyroid, the terminal ileum, tumor tissue, the uterus, the digestive tract and the tongue.
  • the cells or tissue fragments isolated with the aid of the mixtures described are particularly suitable for use in cell and tissue transplantation, as well as in gene therapy (e.g. islets of Langerhans, islet cells, hepatocytes, tumor cells, adipocytes), in immunotherapy or in Wound treatment.
  • gene therapy e.g. islets of Langerhans, islet cells, hepatocytes, tumor cells, adipocytes
  • immunotherapy e.g. islets of Langerhans, islet cells, hepatocytes, tumor cells, adipocytes
  • Wound treatment e.g. islets of Langerhans, islet cells, hepatocytes, tumor cells, adipocytes
  • hybrids according to the invention are particularly advantageous.
  • a well-defined mixture of 2 collagenases with different substrate specificity and one elastase has proven to be ideally suited for the isolation of hepatocytes from rat liver (application examples A, D, E) and human liver (application example F) from bile duct epithelial cells
  • Rat livers application example G
  • endothelial cells from human umbilical cords
  • application examples I and islet cells from porcine pancreas
  • Another main area of application is wound treatment.
  • the enzymes are used in the highest possible purity.
  • collagenase HP and collagenase AZ were collected in separate fractions.
  • the two separate enzyme fractions of collagenase HP and collagenase AZ were concentrated to 50-100 ml with the aid of an ultrafiltration membrane (cutoff limit 10,000 Da), then dialyzed against water and again through an ultrafiltration membrane (cutoff limit 10,000 Da) to approx. 10 liters concentrated.
  • the collagenase HP was eluted from the column with buffer C (20 mM TRIS / HCl + 200 mM NaCl, pH 7.5) in purified form.
  • Collagenase HP got its name * HP "because of its property to break down the hexapeptide Z-Gly-Pro-Gly-Gly-Pro-Ala particularly well. It is therefore suitable for a specific detection of the activity.
  • Collagenase HP is characterized in that it can only convert denatured collagens such as gelatin or azocoll to a small extent, but it attacks bovine tendon collagen and cleaves the synthetic peptides mentioned in Example 2b between glycine and glycine or between any amino acid and glycine with high conversion.
  • collagenase HP together with collagenase AZ (vice-versa, i.e. also any mixture of at least collagenase HP and AZ) has an over-additive effect on the degradation of native collagen. This synergistic effect in vitro is also important when used for tissue integration (e.g. application example G).
  • the specific activity of collagenase HP is a maximum of 146 U / mg in the test with the synthetic substrate Z-Gly-Pro-Gly-Gly-Pro-Ala (11). This corresponds to an approximately 100-fold increase in their specific activity compared to the starting material.
  • the collagenase HP purified in this way forms only a single band both in SDS gel electrophoresis and in isoelectric focusing and electrophoresis on agarose gel.
  • the fine purification of collagenase AZ was carried out on the anion exchanger Mono Q (HR 10/10, Pharmacia) and with the aid of the FPLC device from Pharmacia.
  • a mixture of 1 ml of buffer D and 1 ml of the fraction containing collagenase AZ (from the metal chelate described above) was added to the column, which had been equilibrated with buffer D (20 mM calcium acetate, pH 7.2). Affinity chromatography).
  • collagenase AZ was eluted from the column with buffer E (20 mM calcium acetate, pH 5.0).
  • the collagenase AZ received its designation * AZ "due to its property of degrading the substrate azocolla particularly well. It is characterized in that it converts denatured collagens such as gelatin or azocolla, but also bovine tendon collagen well. However, it is capable of small synthetic peptides such as 2 -Furanacryloyl-Leu-Gly-Pro-Ala, 4-phenyl-azobenzyloxy-carbonyl-Pro Leu-Gly-Pro-Arg and Z-Gly-Pro-Gly-Gly-Pro-Ala.
  • collagenase AZ The specific activity of collagenase AZ is a maximum of 82 U / mg in that of Mandl et al. (12) developed test using Azokoll as substrate. This corresponds to an approximately 80-fold increase in their specific activity compared to the starting material.
  • the collagenase AZ purified in this way forms only a single band both in SDS gel electrophoresis and in isoelectric focusing and electrophoresis on agarose gel. Its molecular weight determined by SDS gel electrophoresis is 111,000 Da. Their isoelectric point is at pH 5.9-6.1.
  • the first cleaning step of elastase was carried out by protein precipitation with ammonium sulfate, as described under l.a. described.
  • the protein precipitate AI is dissolved in 1 L of water, concentrated to about 170 mL via an ultrafiltration membrane (cutoff limit 10,000 Da) and dialyzed against a 0.1 mM calcium acetate solution. The enzyme solution was then again concentrated over an ultrafiltration membrane (cut-off limit 10,000 Da) to approximately 50 mL and then lyophilized.
  • the fine purification was carried out by gel chromatography on SEPHADEX G100 or G200 (Pharmacia).
  • the elastase is characterized in that it can break down elastin with high conversion. Their specific activity (see 3.c.) was 18 U / mg. This corresponds to an approximately 80-fold increase in their specific activity compared to the starting material.
  • the elastase purified in this way forms only a single band in SDS gel electrophoresis as well as in isoelectric focusing and electrophoresis on agarose gel.
  • the molecular weight of the elastase determined by SDS electrophoresis is 35,000 Da. c. Activity determination
  • the factor F is determined by completely dissolving 10 mg elastin of a certain batch with the aid of elastase and measuring the corresponding extinction difference ⁇ E.
  • the multiplication of this factor F by the extinction difference ⁇ E gives the dissolved milligram amount of elastin per mL test batch.
  • Clostripain was isolated by the method described by Ullmann and Jakubke (14).
  • the thiol protease clostripain is characterized in that it cleaves specifically behind the amino acid L-arginine in polypeptide chains and in synthetically produced substrates.
  • Hepatocytes were isolated using the standard Berry and Friend method (9) and the modification by Seglen (16).
  • Wistar rats 200-280 g were anesthetized by ip injection of nembutal (35 mg pentobarbital / kg body weight).
  • the vena portae was cannulated, and the following carbogen-gassed solutions with a pH value of 7.4 ⁇ were subjected to constant hydrostatic pressure (12 cm water column, variable flow rate) 0.05 infused at a temperature of 36-36.8 ° C after opening of the inferior vena cava:
  • Carbogen gas mixture of 95% 0 2 and 5% C0 2 (v / v)
  • the enzyme mixture was a lyophilizate of 130 U collagenase HP, 5 U collagenase AZ and 21 U elastase, which was dissolved in 87.5 mL cell buffer.
  • the proportion of vital hepatocytes, hepatocyte-cell pairs or multicellular aggregates from hepatocytes was determined microscopically after resuspension of the cell precipitate obtained in a Burker count (staining with 0.08% trypan blue, for 2 minutes). Result
  • the enzyme mixture used was a lyophilisate of 130 U collagenase HP, 5 U collagenase AZ and 21 U elastase, which was in 87.5 ml cell buffer (analogous to example A).
  • the success of the isolation of hepatocytes was measured using the following five parameters: 1. microscopic determination of the proportion of vital hepatocytes (in% of the total number of hepatocytes in the cell suspension obtained by means of a trypan blue exclusion test), 2. determination of the total number of isolated hepatocytes, 3. determination measurement of the total number of hepatocytes isolated per gram of animal weight, 4. determination of the proportion of single cells (in% based on all forms of aggression in the cell suspension obtained, ie compared to two and multiple aggregates of hepatocytes), and 5. recording of the success rate Tissue disintegration necessary perfusion time with the collagenase solution.
  • Hepatocytes were isolated using the standard Berry and Friend method (9) and the modification by Seglen (16).
  • the enzyme mixture used was a lyophilizate of 130 U.
  • the quality of the cell suspension obtained was further characterized with regard to the function of the hepatocytes (21, 22) by the following parameters: ATP content, energy charge (EC), lidocaine metabolism to monoethylglycine xylidide (MEGX), and absorption of cholyItaurin ((3 ⁇ , 7 ⁇ , 12 ⁇ -trihydroxy-5ß-cholan-24-oyD-2-aminoethanesulfonic acid) at a substrate concentration of 21 ⁇ -M.
  • the hepatocytes isolated with an enzyme mixture according to the invention not only after assessment by the simple isolation success, but also after evaluation of various cell functions, e.g. certain functions of differentiated mass transport, or certain metabolic performances of cytochrome P450-dependent enzymes of the hepatocytes, are completely intact.
  • Hepatocytes were isolated by the Berry and Friend method (9) and the modifications by Seglen (16) using a Biopsy perfusion technique (21).
  • the enzyme mixture used was a lyophilizate of 130 U collagenase HP, 5 U collagenase AZ and 21 U elastase, which was dissolved in 50 mL cell buffer.
  • the success of the isolation of human hepatocytes was determined according to the following parameters: proportion of vital cells after the trypan blue exclusion test and cell yield per g of liver.
  • biliary epithelial cells from the rat liver were isolated according to the method described in reference (18).
  • hepatocytes were first removed enzymatically from the tissue, and in a second step biliary epithelial cells were isolated from the remaining tissue with trypsin.
  • the enzyme mixture for removing the hepatocytes was a lyophilizate of 130 U collagenase HP, 5 U collagenase AZ and 21 U elastase, which was dissolved in 87.5 mL cell buffer.
  • the use of the enzyme mixture described made it extremely easy to isolate biliary epithelial cells from the remaining vascular system using trypsin, since the residual tissue obtained after the first step was practically free of hepatocytes.
  • Human umbilical vein endothelial cells were isolated using the method of Jaffe (17). For this purpose, the umbilical cords (20 - 30 cm long) were halved, filled in pairs with the respective enzyme solution and incubated for 15 min at 37 ° C and 5% CO 2 in the incubator. The detached cells were removed and kept in primary culture for evaluation. The yield of living and Divisible cells were determined after washing the non-adherent cells after four days in culture.
  • the enzyme mixture was a lyophilizate of 130 U collagenase HP, 5 U collagenase AZ and 21 U elastase, which was dissolved in 87.5 mL cell isolation buffer.
  • the confluent cell lawn consists of over 95% endothelial cells, such as FACS studies with antibodies against factor VIII-related antigen (Von Willebrand factor) or two endothelium-specific surface antigens (EN-4, PAL-E) or with a fluorescent ligand of the scavenger receptor (dil-Ac-LDL).
  • the yield (n 2) achieved with the above-mentioned mixture of purified enzymes exceeded that which had been obtained with enzyme preparations containing collagenase and having an undefined composition.
  • the cell density after 4 days was 1.8 x IO 4 per cm 2 . If you use previously known methods, you get a cell density that is significantly lower. The confluence of the monolayer was reached earlier (already after 5-6 days) when using the above mixture.
  • the prepared cells were functionally checked in the first passage (endothelin production, release of LDH). All values were within the normal range. The functions of the cells were therefore indistinguishable from results from control experiments in which cells with preparations containing collagenase containing an undefined composition were isolated.
  • Tumor cells were isolated from human tumors according to protocol (23).
  • the enzyme mixture used was a lyophilizate of 130 U
  • Collagenase HP 5 U collagenase AZ and 21 U elastase, which was dissolved in 28.4 L cell isolation buffer (Ringer's lactate / PBS).
  • the success of the isolation was determined on the basis of the proportion of vital cells after the trypan blue exclusion test and counting of the number of lymphocytes. Directly comparative cell isolations were carried out using the enzyme mixture according to the invention and a preparation of an undefined composition containing collagenase, which is very suitable for this purpose, in 4 different tumor tissues.
  • the enzyme mixture according to the invention can be used very well to isolate tumor cells from human tumors.
  • the collagenase solution acts on the pancreatic tissue for a long time after infusion through the pancreatic duct under particularly well-standardized conditions.
  • the islands which have already been detached are continuously discharged into a reservoir at a lower temperature, and after the disintegration has ended, the islands which have already been partially freed from their matrix in the pancreatic tissue are completely detached and isolated using light mechanical treatment.
  • the success of the isolation can be determined on the basis of the size distribution of the intact cell aggregates obtained and other customary parameters.
  • mixtures could also be used successfully, for example those composed of collagenase HP (3-48 U / cm 2 ) and elastase (1-12 U / cm 2 ).
  • Example K The results obtained on the degrading effect of the necrotic tissue (Example K) were characterized further in an in vitro model.
  • the release of 4-hydroxyproline (20) was determined after 2, 4, 6 and 24 hours by the action of collagenase HP, collagenase AZ and / or elastase on the burn scab mentioned in Example K.
  • the purified enzymes and enzyme mixtures according to the invention can also be used in therapeutic areas, such as in wound treatment or for the treatment of keloids or fibrils. They can be applied externally or injected.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
EP96907436A 1995-03-16 1996-03-12 Neue, definierte enzymmischungen zur zellgewinnung und für die wundbehandlung Withdrawn EP0815211A1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19509584 1995-03-16
DE19509584 1995-03-16
DE19532906A DE19532906A1 (de) 1995-03-16 1995-09-07 Neue, definierte Enzymmischungen zur Zellgewinnung und für die Wundbehandlung
DE19532906 1995-09-07
PCT/EP1996/001044 WO1996028543A1 (de) 1995-03-16 1996-03-12 Neue, definierte enzymmischungen zur zellgewinnung und für die wundbehandlung

Publications (1)

Publication Number Publication Date
EP0815211A1 true EP0815211A1 (de) 1998-01-07

Family

ID=26013440

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96907436A Withdrawn EP0815211A1 (de) 1995-03-16 1996-03-12 Neue, definierte enzymmischungen zur zellgewinnung und für die wundbehandlung

Country Status (13)

Country Link
US (1) US6146626A (cs)
EP (1) EP0815211A1 (cs)
JP (1) JPH11501517A (cs)
AU (1) AU702514B2 (cs)
BR (1) BR9607143A (cs)
CA (1) CA2213723A1 (cs)
CZ (1) CZ280397A3 (cs)
EA (1) EA000583B1 (cs)
HU (1) HUP9901188A2 (cs)
IL (1) IL117479A (cs)
NO (1) NO974260L (cs)
PL (1) PL322271A1 (cs)
WO (1) WO1996028543A1 (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718897A (en) * 1995-06-07 1998-02-17 Trustees Of Tufts College Enhancing keratinocyte migration and proliferation
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
WO2003011333A1 (en) * 2001-07-27 2003-02-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
US7364565B2 (en) 2001-07-27 2008-04-29 Ramot At Tel Aviv University Ltd. Controlled enzymatic removal and retrieval of cells
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
US8323642B2 (en) * 2006-12-13 2012-12-04 Depuy Mitek, Inc. Tissue fusion method using collagenase for repair of soft tissue
US20100159564A1 (en) * 2007-11-30 2010-06-24 Dwulet Francis E Protease resistant recombinant bacterial collagenases
MX2012006661A (es) 2009-12-08 2012-11-12 Healthpoint Ltd Composiciones enzimaticas de desbridamiento de heridas con actividad enzimatica mejorada.
HUE057423T2 (hu) 2012-01-12 2022-05-28 Endo Global Ventures Clostridium histolyticum enzim
CN115969318A (zh) 2017-03-01 2023-04-18 恩多风投有限公司 用于评估和治疗橘皮组织的装置和方法
AU2018244426A1 (en) 2017-03-28 2019-10-17 Endo Ventures Limited Improved method of producing collagenase
CN109694845A (zh) * 2018-12-25 2019-04-30 中国医学科学院北京协和医院 用于分离单细胞的试剂盒及其应用
WO2023228873A1 (ja) * 2022-05-24 2023-11-30 国立研究開発法人国立成育医療研究センター 肝細胞の製造方法、肝細胞の接着性改善剤、および肝細胞

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0673456B2 (ja) * 1986-04-26 1994-09-21 三共株式会社 ヒト・膵臓エラスタ−ゼ▲ｉ▼
US5162205A (en) * 1986-04-26 1992-11-10 Sankyo Company, Limited Human pancreatic elastase I
AU4644793A (en) * 1992-06-22 1994-01-24 Trigen, Inc. Molecular cloning of the genes reponsible for collagenase production from clostridium histolyticum
WO1996000283A1 (en) * 1994-06-24 1996-01-04 Boehringer Mannheim Corporation A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9628543A1 *

Also Published As

Publication number Publication date
CZ280397A3 (cs) 1998-04-15
HUP9901188A2 (hu) 1999-08-30
IL117479A0 (en) 1996-07-23
JPH11501517A (ja) 1999-02-09
EA000583B1 (ru) 1999-12-29
WO1996028543A1 (de) 1996-09-19
EA199700241A1 (ru) 1998-02-26
IL117479A (en) 1999-12-22
PL322271A1 (en) 1998-01-19
CA2213723A1 (en) 1996-09-19
US6146626A (en) 2000-11-14
BR9607143A (pt) 1997-11-25
AU702514B2 (en) 1999-02-25
NO974260D0 (no) 1997-09-15
AU5106696A (en) 1996-10-02
NO974260L (no) 1997-11-14
MX9706725A (es) 1997-11-29

Similar Documents

Publication Publication Date Title
DE69735308T2 (de) Enzymzusammensetzung für die freisetzung von zellen aus geweben.
DE69823361T2 (de) Herstellung von kollagen
DE60115613T2 (de) Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
DE2734821C3 (de) Blutgerinnungsfördernde Präparation und Verfahren zu ihrer Herstellung
EP0815211A1 (de) Neue, definierte enzymmischungen zur zellgewinnung und für die wundbehandlung
US20030203008A1 (en) Preparation of collagen
DE68918922T3 (de) Biologische Unterlage für Zellkulturen, bestehend aus durch Thrombin koagulierte Plasmaproteine, ihre Verwendung für die Keratinozytenkultur, deren Rückgewinnung und Transport für therapeutische Verwendungszwecke.
EP0209061A2 (de) Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel
DE69333239T2 (de) Reinigung von plasmafraktion
WO1996034093A1 (en) Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells
DE2619667A1 (de) Pharmazeutisches mittel
DE3617752A1 (de) Gewebe-plasminogenaktivator, diesen enthaltende pharmazeutische formulierungen, ihre herstellung und ihre verwendung in der human- und veterinaermedizin
DE3230151A1 (de) Neues polypeptid mit wirkung auf das immunsystem, verfahren zu seiner isolierung und reinigung, seine verwendung, dieses enthaltende mittel sowie seine spaltprodukte, deren verwendung und diese enthaltende mittel
DE2734427A1 (de) Verfahren zur gewinnung von thrombinartigen enzymen aus schlangengiften
EP1056839A1 (de) Pharmazeutische formulierung enthaltend ein hyaluronsäure-spaltendes enzym mikrobieller herkunft
DE19532906A1 (de) Neue, definierte Enzymmischungen zur Zellgewinnung und für die Wundbehandlung
DE3306944A1 (de) Fibrinolytisch aktives mittel und verfahren zu seiner herstellung
JPWO2002102845A1 (ja) 絹フィブロイン由来機能性ポリペプチドの製造法及びその利用
AT392003B (de) Verfahren zur herstellung eines insbesondere zur wundheilung oder zur behandlung in der geriatrie verwendbaren wirkstoffes aus saeugetierblut durch papainhydrolyse und ein einen solchen wirkstoff enthaltendes praeparat
WO1998001108A1 (de) Definierte enzymmischungen für kosmetische zwecke
DE19716098A1 (de) Fibroblasten mit einem Fremdgen enthaltende Zusammensetzung zur Behandlung von Wunden
DE4002166A1 (de) Verfahren zur herstellung einer suspension zur rekonstruktion von zellmembranen
DE69634090T2 (de) Verfahren zur verhinderung der aktivität des chymopapain- und ppainenzyms mit tierischen polysacchariden
DE2106706B2 (de) Verfahren zur herstellung von pankreatin als trockenes pulver mit hoher proteolytischer, amylolytischer und lipolytischer aktivitaet
WO2007143978A2 (de) Verfahren zur induktion der insulinsynthese in chorionzellen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970822

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB IT LI NL PT SE

17Q First examination report despatched

Effective date: 20000623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020522